Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with RelapsedRefractory Chronic Lymphocytic Leukemia

Abstract EN

Background.

Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection.

We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subcutaneous alemtuzumab (OFSA) for the treatment of relapsed/refractory CLL.

Results.

Depending on their response, patients were given two to six 28-day cycles of subcutaneous alemtuzumab 30 mg on days 1,3, and 5 and oral fludarabine 40 mg/m2/day for 5 days.

Median patient age was 74.

The lymphocyte counts of all five patients fell after the 1st cycle of treatment and reached normal/low levels on completion of 2 to 6 cycles of therapy.

Platelet counts and hemoglobin were unaffected.

All five patients achieved complete hematological remission, while two attained minimal residual disease negativity on 4-color flow cytometry.

Conclusions.

Our OFSA regimen was effective in elderly Asian patients with relapsed/refractory CLL, and it should be investigated further.